Other brands: Prevenar 13® (PCV13)
Vaccine type: subunit conjugate
Schedule and administration
Synflorix will be administered on the routine National Immunisation Schedule from approximately mid-August at 6 weeks, 3 months and 15 months of age. Healthy children who missed these events can catch up at any time up to their 5th birthday.
Prevenar 13 is recommended and funded for children and adults with a medical condition that increases their risk of invasive pneumococcal disease AND is listed on the Pharmaceutical Schedulee. Children with a medical condition that increases their risk of invasive pneumococcal disease AND is listed on the Pharmaceutical Schedule be funded to receive Prevenar 13 vaccine in place of Synflorix. Prevenar 13 is available for purchase by people with a medical condition that is not listed on the Pharmaceutical Schedule.
Healthy children under 5 years who have not completed a course of PCV vaccine are eligible to receive age-appropriate catch up doses. The required number of doses are determined by the age of the child and whether they completed a course of PCV in their first year of life (i.e. three doses if commenced aged under 7 months or two doses if commenced between 7–11 months). Refer to Appendix 2 in the Immunisation Handbook 2017: Planning immunisation catch-ups.
Note: Two catch-up doses of Synflorix are required for children aged 2–5 years. This is different to the number of catch-up doses of Prevenar 13 for this age group (one dose).
Table 1: Synflorix (PCV10) catch up schedule
Number of doses required
≥ 6 weeks– ≤ 6 months
3a + 1b
7 – 11 months
2a + 1b,c
12 months – < 5 years
1 + 1c,d
a At least 4 weeks between doses
b The ‘+ 1’ dose is a booster given in the second year of life (at the 15 month immunisation event)
c At least 8 weeks after previous dose
d If a primary course was completed in the first year only one dose is required
Storage and preparation
Store as per cold chain between 2°C to 8°C. Protect from light.
Synflorix can be administered concurrently with other vaccines, including all the National Immunisation Schedule vaccines except other pneumococcal vaccines, e.g. Prevenar 13, Pneumovax 23. Separate syringes and different injection sites should be used.
Administration of Synflorix is by intramuscular injection into the vastus lateralis muscle in infants and the deltoid muscle in toddlers and children. No data are available on subcutaneous administration of Synflorix.
Synflorix should not be given to:
- Anyone with severe allergy (anaphylaxis) to a previous dose of this vaccine or other pneumococcal conjugate vaccines, or a component of the vaccine
- Administration of Synflorix should be postponed in individuals suffering from a fever over 38°C. The presence of a minor infection is not a reason to delay immunisation
Invasive pneumococcal disease
Surveillance in New Zealand reported that IPD notifications reduced by around two-thirds in infants following the 2011 switch from PCV7 to PCV10.
Finland FinIP, the largest study to be conducted on PCV-10, found vaccine effectiveness (VE) against culture-confirmed vaccine-serotype IPD was 100% following a three-dose primary series and a booster in the second year of life (3+1 schedule). Rates of non-laboratory confirmed IPD in children aged 3–42 months declined by two-thirds following the introduction of PCV10.
In Latin America, during the COMPAS study, 100%. VE was also shown against IPD.
Brazil Age-appropriate PCV10 immunisation was shown to be 83.8% effective overall against IPD, including 82.2% effectiveness against cross-reactive serotype 19A. Following the initiation of the PCV10 vaccination programme, mortality from pneumococcal meningitis decreased by 69% in infants aged <2 years and the number of cases halved, particularly in those aged 6–11 months.
Canada At least one dose of PCV10 was shown to be 97% effective against vaccine-type IPD in children aged under 5 years, 72% effective against any IPD, and had a 71% cross-reactive VE against serotype 19A IPD. When comparing at least two doses of PCV7, PCV10 or PCV13, VE did not differ against vaccine-type IPD.
Decreases in pneumonia hospitalisation in infants were observed in Brazil, Latin America and Finland following the introduction of PCV10 immunisation of infants. VE against all infant pneumonia hospitalisations was calculated to be around 25% in the FinIP trial.
PCV 10 has been shown to provide protection against pneumococcal acute otitis media (AOM) in Latin American and Indigenous Australian children. In New Zealand, a decline in incidence of otitis media in children aged under 6 years has been observed since the introduction of PCV to the childhood immunisation schedule from 2006 in special groups and 2008 universally. During the PCV7 usage time period OM incidence declined by 55%, then by 66% during the PCV10 period and 81% during the PCV13 period. These declines were greatest in the children of Māori and Pacific ethnicity, resulting in little ethnic disparity in disease incidence between the main ethnic groups. Following the introduction of PCVs in New Zealand, the dominant pathogen associated with otitis media became NTHi, which was detected in 95% of children requiring surgery for otitis media. Due to conjugation of eight of the ten vaccine-type polysaccharides with NTHi protein D, it has been suggested that PCV10 may also protect against this major cause of AOM in children. However, the data is not conclusive.
There is evidence from the FinIP study that PCV10 immunisation initiated prior to 12 months of age may reduce the frequency of tympanostomy tube placements (TTP, grommets). The FinIP study also found that there were fewer outpatient prescriptions for antimicrobial drugs used to treatment AOM following immunisation with PCV10 (VE ranging from 3–8% across study cohorts)
Vaccination with PCV10 reduces nasopharyngeal carriage (NPC) of vaccine-type pneumococci. The FinIP study found that NPC was reduced by 19-56% in infants aged under 2 years immunised with PCV10 (as 3+1 schedule). The COMPAS study showed a 25.6% (reduction in NPC for vaccine-serotypes. Following a three-dose primary series in Brazil, NPC was reduced by 44%. Carriage of vaccine-type pneumococci declined from 34% to 13% in vaccinated Kenyan children following the introduction of PCV10 to the childhood schedule. The reductions in NPC were shown to persist for at least 28 months following a 3+1 infant schedule of PCV10 in the Czech Republic.
PCV10 immunisation was not found to reduce NTHi carriage in the COMPAS, FinIP and other studies. A Dutch study also found that effect of PCV10 on NTHi NP colonisation in healthy children was no greater than that from PCV7 vaccination.
In New Zealand, the carriage of PCV10 serotypes, but not NTHi, declined in children aged under 3 years following the introduction of the vaccine to the childhood schedule. There was an increase in NP carriage of non-vaccine type 19A in New Zealand children.
PCV10 immunisation has been shown to have indirect population-wide effects (herd immunity) on vaccine-specific disease, including in New Zealand. A reduction in IPD cases of 48% among unvaccinated children aged 2–5 years was observed following the introduction of the PCV10 vaccination programme in Finland. In Kenya, the PCV10 had 66% effectiveness among unvaccinated individuals aged ≥5 years against NP carriage of pneumococcal vaccine-serotypes. This reduction in transmission may lead to a reduction in vaccine-type IPD in all age groups.
In New Zealand, significant reductions of 60% and 70% were observed in vaccine-serotype IPD notifications in those aged 5–64 years and over 65 years, respectively, between 2006 and 2014. However, no corresponding decline was seen in the overall IPD rate for the non-target age groups.
Synflorix will not protect against pneumococcal serogroups other than those included in the vaccine. Although antibody response to diphtheria toxoid, tetanus toxoid and Protein D (Protein D is highly conserved in all Haemophilus influenzae strains including NTHi) occurs, immunisation with Synflorix does not substitute routine immunisation with diphtheria, tetanus or Haemophilus influenzae type b vaccines.